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clin therapy and 22 children and 13 adults had repeat studies after 1 year
of chronic PG12.At baseline, 79% of the children and 87% of the adults had
abnormal platelet function. In addition, Factor Vlll, von Willebrand antigen
and ristocetin cofactor levels were abnormally high in 29%, 16% and 16%,
respectively, in the children, and in 92%, 72?. and 52Y0,respectively, in the
adults. On chronic PGIz therapy, platelet function normalized in 80% of the
children and in 83% of the adults who had platelet dysfunction at twseline(p< 0.01). Factor Vlll, von Willebrand antigen and ristocetin cofactor also
decreased on chronic prostacyclin in both the children and adults (p < 0.02).
In addition, the ratio of ristocetin cofactor to VW antigen, which may reflect
biological activity of VW Factor, increased on chronic PGIz in the adults from
an abnormally low level (0.56 * 0.22) to normal (1.12 & 0.42), and in the
children the ratio increased from 0.83 * 0.30to 1.26 *0.38 (normal 0.6-1.4).
In conclusion, these alterations in the coagulation system may contribute to
the pathogenesis of PPH and the normalization of these endotheiial markers
on chronic PG12therapy suggests that long-term prostacyclin remodels the
pulmonary vascular bed with subsequent decrease in endothelial cell injury.
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m Modeof DeathinAdultewithCongenitalHeart
— Diaeaae
E.N. Oechslin, D.A. Harrison, M.S. Connelly, C3.D.Webb, S.C. Siu. The
TorontoHospital, Toronto, ON, Canada
The cause of death in adults with congenital heart disease (CHD) has not
been well defined. We reviewed the outcomes of patients (pts) followed by
the Toronto Congenital Cardiac Centre for Adults (TCCCFA)during the years
1961-1996. Mortality and mechanism of death were obtained from health
records, next of kin, family physicians and the provincial death registry.
Pts transferred from out of province or directly referred for surgery were
not included. Simple anatomy was defined as atrial or ventricular septel
defect, patent ductus arIeriosus, bicuspid aortic valve, coarctation of the
aorta or primary pulmonary hypertension. All other defects were classified as
complex. Sudden death wae defined as death within one hour of previously
stable condition.
Ffesu/ts:Of the 2532 ptsseen during the study period at TCCCFA, 150 pts
(65 females, 85 males) are known to have died at average age 36.2• 14.0
yre. 59 of the deceased pts (39%) had a simple defect, 91 (61%) a complex
lesion. 41 pts have not had cardiac surgery.
33 deaths (22%) occurred intra- and postoperatively related to cardiac
eurgety. 36 pts (25%) had sudden deaths (92~o attributed to arrhythmia). 30
pts (20%) died due to heart failure: 8 (4%) arrhythmia non-sudden, 8 (5%) of
endocerditis, 11 other cardiac (7Yo)and 24 (18%) non-cardiac.
Conclusion.’The 3 major causes of death in adults with CHD are sudden,
peri-operative and heart failure. Reduction of mortality for this population will
require identification of risk factors for these complications.
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n7951 Gender-relatedlfferenceainatherosclerosis:Role
ofendothelin-1in proliferationofvaacularsmooth
musclecells
D.M. Antoniucci, V.M. Miller, L.A. Fitzpatrick. Departments ofhfedicine and
Surgery Mayo Clinic and Mayo Foundation, Rochestec MN, USA
Proliferation of vascular smooth muscle cells (VSMC) has been implicated in
thepathogenesis ofcoronefyarlery disease. Theincidence of atherosclerosis
varies greatly among men, postmenopausal women, and estrogen-replete
women. However, the mechanism by which sex steroid hormones leads
to differences in the expression of gender-related coronary artery disease
has not been mmpletely elucidated. Vascular smooth muscle cells contain
ETA receptors for endothelin-1 (ET-l), and receptors for estradiol and dihy-
drotestoeterone. Restudied theeffecfof ET-I on the proliferation of coronary
vascular smooth muscle cells obtained from sexually mature, gonadally intact
female and male pigs. VSMC were iedated via explant and growth-arrested
in serum-free, phenol red-free media, Effectore (ET-1, p-estradiol, (pE2), or
vehicle) were added (10-10-106 M) for 24 hours and proliferation assessed
bythymidine incorporation. In VSMCSobtained from sexually mature female
animals, ET-1 significantly inhibited coronary VSMC proliferation (p <0.005
by ANOVA). When ET-1 and A4EZwere added, the inhibition was greater
than with @E2alone. In contrast, ET-1 did not affect mitogenesis in coronary
VSMCSderived from sexually mature male animals. A significant difference
(p <0,001 by ANOVA) was noted in the response to ET-1 in male versus
female cells. VSMC were isolated from female animala that were oophorec-
tomized. ET-1 had no effect on proliferation of VSMC derived from this
estrogen-deplete environment. We conclude that the cardioprotective effect
of estradiol includes inhibition of VSMC proliferation by endothelin; this effect
is lost in male and estrogen-deplete (oophorectomized) female animals.
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1795+1AcuteAdmini~trationof~Pecifi~~ndothe,in-A
ReceptorAntagonist,Attenuates
Endothelin-inducedbutnotAcetyicholine-lnduoed
CoronaryVasoconstrictionin Experimental
Hypercholeaterolemia
D, Hasdai, C.R. Cannan, V, Mathew, R.S. Schwartz, D,R. Holmes, Jr.,
A. Lerman. The Mayo Clinic, Roc/resteL A4JV,USA
Endothelin (ET) may participate in the coronary vasoconstriction associated
with endothelial dysfunction, This study was to designed to teet whether
acute administration of FR-139317, an ETA-receptor antagonist, attenuates
thecorona~ vasoconstrictor response to acetyicholine (Ach) in experimental
hypercholesterolemia (HC). The percent change in coronary artery diameter
(% ACAD) to intracoronarY infusions of eitherET-1 (5 rig/kg rein) or Ach
(lO-eMto 10-4M), each with co-infusion of either intracoronary normal saline
or FR-139317 (5 @kg minute), were meaeured by quantitative coronary
angiography in pigs. The studies were repeated after 10 weeks of high-
cholesterol diet. At 10 weeks there was a significant increase in plasma
cholesterol and circulating ET. FR-139317 alone did not affect systemic or
corona~ hemodynamics.
“AACAD ET(n = 5) ET+ FR(n= 6) Ach(n = 7) Ach+ FR(n= 6)
Bsseline –IS*8 –12+6 5*2 7*3
10wks.HC –77* 14” –14& 6t –23+ 12* –19* 7“
*p <0.05 Bassvs.HC,tp <0.05 FRvs.normalsaline.
We conclude that acute intracoronary administration of FR-139317 in
HC attenuates the anhanced epicardial coronary vasoconstricfor effects of
exogenously administered ET. However, FR-139317 at this dose dose not
attenuate Ach-induced coronaw vasoconstriction. Thus, tha ETA receptor
may not mediate Ach-induced coronary epicardial vasoconstriction in HC.
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Responsesto Adenosineandthe Dagreeof
AttenuationISIncreasedby EndothelialDysfunction
C.A. Davis Ill, A.J. Sherman, K.R. Hartis, S. Hedjbeli, Y. Yaroshenko,
F.J. Klocke. Feinberg Cardiovascular Research Institute, N6rthwestem
Univerai~, Chicago, IL, USA
Glyburide, a commonly used sulfonykrrea, is known to block ATPdependent
potassium channels, which play an important role in coronary vasodilatory
responses. These responses also depend on endothelial-derived factors,
particularly nitric oxide. Accordingly, we have studied the effects of glyburide,
with and without concomitant blockade of nitric oxide synthesis, on responses
of coronary flow to graded intracoronary infusion of adenosine (l&1,000
@rein) in seven chronically instrumented dogs. The EDm of dose-response
cuwes relating coronary conductance to adenosine concentration wae unaf-
fected by eystemic administration of 0.3 mg/kg glyburide (0.93 * 0.31 [SEM]
vs. 1.35 * 0.56 @ml, NS). ED50 increased systematically, however, foi-
Iowing 1.0 mg/kg glyburide (3.53 + 1.09 #@ml, p <0.05 ANOVA). When
nitric oxide synthesis was blocked (L-NAME, 1 mgJkgIV), glyburide-induced
reductions in adenosine responsiveness were augmented. The absolute in-
crease in ED50in reeponse to 0.3 mg/kg glyburide rose from 0.42 ~ 0.29 to
1.62 * 0.93 @ml (p -=0.05), and following 1.0 mg/kgglyburidefrom2.60
+ 0.99 to 13.0 * 6.47 #@ml (also p < 0.05). We conclude that sulfonylurea
therapy can attenuate coronary vasodilatoy responsesto adenosine,and
that the degreeof attenuationis augmentedin the preeenceof endothelial
dysfunction.
